SIGA Technologies - Additional approvals expected shortly
SIGA recently reported Q321 results, which featured $2.3m in oral TPOXX purchases by the Canadian Department of National Defence (CDND). Importantly, the US Biomedical Advanced Research and Development Authority (BARDA) has exercised its procurement option valued at $112.5m, with product deliveries targeted to occur by the end of 2021 (approximately 30% of the procured product was delivered in October alone). The company, however, has indicated that COVID-19 related supply chain issues may delay some of the deliveries, though it is working diligently to avoid that.SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The company's primary product is an oral formulation of TPOXX?, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The United States Food and Drug Administration has approved oral TPOXX? for the treatment of smallpox.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.